Novartis International AG http://www.novartis.com Novartis delivers excellent performance in third quarter: recently launched products generate 20%* of sales; Gilenya approved; Alcon consolidated 2010-10-21T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1453762.shtml Novartis obtains CHMP positive opinion for its investigational pre-pandemic influenza vaccine Aflunov® to help protect against (H5N1) avian influenza 2010-09-24T17:38:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1446813.shtml Novartis Phase III study shows meningococcal B vaccine candidate could be first to provide broad coverage against deadly disease 2010-09-12T17:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1443940.shtml Novartis delivers strong financial performance in second quarter, underpinned by increased momentum in innovation 2010-07-15T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1431809.shtml Novartis healthcare portfolio generates strong growth in first quarter of 2010, progress on delivering innovation, growth and productivity 2010-04-20T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1405499.shtml Novartis receives approval in the European Union for Menveo®, first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease 2010-03-18T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1395085.shtml Novartis receives FDA approval of Menveo®, a vaccine to prevent meningococcal disease 2010-02-22T07:05:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1386845.shtml Novartis meningococcal vaccine Menveo® recommended for approval in the European Union for prevention of disease in adolescents and adults 2009-12-18T15:24:29 CET http://www.novartis.com/newsroom/media-releases/en/2009/1365021.shtml Novartis erzielt im dritten Quartal eine hervorragende Performance: Die jüngsten Produkte steuern 20%* zum Umsatz bei; Gilenya wird zugelassen; Alcon wird konsolidiert 2010-10-21T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1453748.shtml